Skip to main content
EYPT
NASDAQ Industrial Applications And Services

EyePoint Posts $95.6M Q3 Loss, $118M Cash, Runway Into Late Q3 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.36
Mkt Cap
$30.743M
52W Low
$0.331
52W High
$19.11
52W Position info
8.9% above low
Off High info
98% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

EYPT is trading near its 52-week low of $0.331 (8.9% above the low).

Summary

EyePoint reported a $95.6 million Q3 2026 net loss and $118 million in cash, funding operations only into late Q3 2027 — just past the early-Q4-2027 DME Phase 3 topline readout that now carries the whole company.


Key Events · Earnings and Guidance · EYPT

  • Q3 Loss Widens to $95.6M

    Net loss was $95.6 million, or $1.07 per share, versus $59.7 million, or $0.85 per share, a year earlier, as R&D reached $81.7 million for the quarter.

  • Cash Falls to $118M

    Cash, cash equivalents and marketable securities totaled $118 million at September 30, 2026, down from $306 million at December 31, 2025.

  • Runway Into Late Q3 2027

    Management expects current cash plus $10 million raised after quarter-end under the at-the-market facility to fund operations into late third quarter of 2027.

  • DME Data Due Early Q4 2027

    Phase 3 COMO and CAPRI in DME are fully enrolled with over 550 patients; topline data are expected early in the fourth quarter of 2027, after the stated runway ends.


Analysis · EYPT · Industrial Applications And Services

Strip away the quarterly mechanics and this is a survival statement. Cash stood at $118 million at the end of September, down from $306 million at the start of the year, and management says that balance plus $10 million raised after quarter-end under its at-the-market facility funds operations only into late Q3 2027. That runway lands just after the early-Q4-2027 topline readout for the DME Phase 3 COMO and CAPRI trials, which are now fully enrolled with over 550 patients. With wet AMD wound down after two Phase 3 misses, DME is the entire thesis, and the company will need to raise money or do a deal before that data arrives. Management explicitly flags business development and financing as levers to extend the runway.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EYPT was trading at $0.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $30.7M. The 52-week trading range was $0.33 to $19.11. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EYPT - Latest Insights

EYPT
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.350
Real-time Price: $0.3102 info
Change: -$0.0398 (-11%) info
Market Cap: $26.381M info
EYPT
Nov 12, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.360
Real-time Price: $0.3102 info
Change: -$0.0498 (-14%) info
Market Cap: $26.381M info
EYPT
Oct 19, 2026, 9:22 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5443
Real-time Price: $0.3102 info
Change: -$0.2341 (-43%) info
Market Cap: $26.381M info
EYPT
Oct 19, 2026, 8:08 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.6115
Real-time Price: $0.3102 info
Change: -$0.3013 (-49%) info
Market Cap: $26.381M info
EYPT
Oct 19, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.99
Real-time Price: $0.3102 info
Change: -$2.68 (-90%) info
Market Cap: $26.381M info